JP2019534298A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534298A5
JP2019534298A5 JP2019523836A JP2019523836A JP2019534298A5 JP 2019534298 A5 JP2019534298 A5 JP 2019534298A5 JP 2019523836 A JP2019523836 A JP 2019523836A JP 2019523836 A JP2019523836 A JP 2019523836A JP 2019534298 A5 JP2019534298 A5 JP 2019534298A5
Authority
JP
Japan
Prior art keywords
protein
dux4
composition according
composition
gene editing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019523836A
Other languages
English (en)
Japanese (ja)
Other versions
JP7231226B2 (ja
JP2019534298A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/060410 external-priority patent/WO2018085842A1/en
Publication of JP2019534298A publication Critical patent/JP2019534298A/ja
Publication of JP2019534298A5 publication Critical patent/JP2019534298A5/ja
Priority to JP2023018459A priority Critical patent/JP2023071691A/ja
Application granted granted Critical
Publication of JP7231226B2 publication Critical patent/JP7231226B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019523836A 2016-11-07 2017-11-07 顔面肩甲上腕型筋ジストロフィーのための治療標的 Active JP7231226B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023018459A JP2023071691A (ja) 2016-11-07 2023-02-09 顔面肩甲上腕型筋ジストロフィーのための治療標的

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662418694P 2016-11-07 2016-11-07
US62/418,694 2016-11-07
US201762490783P 2017-04-27 2017-04-27
US62/490,783 2017-04-27
PCT/US2017/060410 WO2018085842A1 (en) 2016-11-07 2017-11-07 Therapeutic targets for facioscapulohumeral muscular dystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023018459A Division JP2023071691A (ja) 2016-11-07 2023-02-09 顔面肩甲上腕型筋ジストロフィーのための治療標的

Publications (3)

Publication Number Publication Date
JP2019534298A JP2019534298A (ja) 2019-11-28
JP2019534298A5 true JP2019534298A5 (cg-RX-API-DMAC10.html) 2020-12-17
JP7231226B2 JP7231226B2 (ja) 2023-03-01

Family

ID=62076463

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523836A Active JP7231226B2 (ja) 2016-11-07 2017-11-07 顔面肩甲上腕型筋ジストロフィーのための治療標的
JP2023018459A Pending JP2023071691A (ja) 2016-11-07 2023-02-09 顔面肩甲上腕型筋ジストロフィーのための治療標的

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023018459A Pending JP2023071691A (ja) 2016-11-07 2023-02-09 顔面肩甲上腕型筋ジストロフィーのための治療標的

Country Status (6)

Country Link
US (3) US11160823B2 (cg-RX-API-DMAC10.html)
EP (2) EP3896451B1 (cg-RX-API-DMAC10.html)
JP (2) JP7231226B2 (cg-RX-API-DMAC10.html)
AU (1) AU2017355712B2 (cg-RX-API-DMAC10.html)
CA (1) CA3042700A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018085842A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US11160823B2 (en) 2016-11-07 2021-11-02 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3684378A4 (en) * 2017-09-19 2021-06-16 Children's National Medical Center GAPMERS AND THEIR USES IN THE TREATMENT OF MUSCLE DYSTROPHY
AU2019255789B2 (en) 2018-04-19 2025-11-20 The Regents Of The University Of California Compositions and methods for gene editing
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
JP2022516515A (ja) * 2018-12-31 2022-02-28 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Rna標的化crispr-cas13bを使用するdux4 rna発現停止
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
AU2021257213A1 (en) * 2020-04-17 2022-11-03 Nevada Research & Innovation Corporation CRISPR-inhibition for facioscapulohumeral muscular dystrophy
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
EP4204556A4 (en) * 2020-08-31 2024-10-02 Modalis Therapeutics Corporation Method for treating facioscapulohumeral muscular dystrophy (fshd) by targeting dux4 gene
JP2022055361A (ja) * 2020-09-28 2022-04-07 田辺三菱製薬株式会社 Dux4の発現を調節するための医薬組成物
JP2024523394A (ja) * 2021-06-17 2024-06-28 エピクリスパー バイオテクノロジーズ, インコーポレイテッド 異常な遺伝子発現を調節するためのシステムおよび方法
WO2022272043A1 (en) * 2021-06-24 2022-12-29 Research Institute At Nationwide Children's Hospital , Inc. Salvianoic acid or adenosine dialdehyde for treating fagcioscapulohumeral muscular dystrophy (fshd)
EP4578943A4 (en) * 2022-08-25 2026-02-25 Fujifilm Corp PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION
CN115896223A (zh) * 2022-10-19 2023-04-04 中国医学科学院基础医学研究所 一种表观调节因子dot1l在肌肉分化中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US20150301067A1 (en) * 2012-11-05 2015-10-22 University Of Washington Through Its Center For Commercialization Methods and assays for facioscapulohumeral muscular dystrophy
WO2014144169A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Carm1 inhibitors and uses thereof
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
US9814728B2 (en) * 2013-09-20 2017-11-14 Saint Louis University Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
WO2016044641A2 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
WO2016044650A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
WO2016044604A1 (en) 2014-09-17 2016-03-24 Epizyme, Inc. Carm1 inhibitors and uses thereof
US10538763B2 (en) 2015-01-16 2020-01-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of DUX4
DK3302522T3 (da) * 2015-06-02 2022-09-26 Academisch Ziekenhuis Leiden Midler og fremgangsmåde til behandling af facioscapulohumeral muskeldystrofi (fshd)
US10933068B2 (en) * 2016-05-26 2021-03-02 Sonic Master Limited Modulators of DUX4 for regulation of muscle function
EP3515506B1 (en) * 2016-09-23 2023-09-13 University of Massachusetts Silencing of dux4 by recombinant gene editing complexes
US11160823B2 (en) 2016-11-07 2021-11-02 University Of Massachusetts Therapeutic targets for facioscapulohumeral muscular dystrophy

Similar Documents

Publication Publication Date Title
Wu et al. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study
US11155796B2 (en) Compositions and methods for epigenome editing
JP2024501383A (ja) エピジェネティック編集のための組成物および方法
EP2850189B1 (en) Compositions and methods for modulating gene expression
EP3170899B1 (en) Microrna mir-155 in neurodegenerative disorders
JP2023071691A (ja) 顔面肩甲上腕型筋ジストロフィーのための治療標的
US11912994B2 (en) Methods for reactivating genes on the inactive X chromosome
Liu et al. MicroRNA‐21 increases the expression level of occludin through regulating ROCK1 in prevention of intestinal barrier dysfunction
Pan et al. Epigenetic regulation of TIMP1 expression by 8-oxoguanine DNA glycosylase-1 binding to DNA: RNA hybrid
US11013754B2 (en) Compositions and methods for treating cancer
CN114901835B (zh) 包含mir-335的组合物
US20210222168A1 (en) Methods for reactivating genes on the inactive x chromosome
US10487328B2 (en) Blocking Hepatitis C Virus infection associated liver tumor development with HCV-specific antisense RNA
CN112662671A (zh) 靶向SMN2启动子区甲基化位点nt-290所在区域的反义寡核苷酸
US20240401012A1 (en) Sgf29 as a target for hox/myc driven cancers
WO2015179656A2 (en) Specific targeted activation of cystic fibrosis transmembrane conductance regulator (cftr)
Pulito et al. Role of microRNA-dependent PTEN downregulation in the resistance to PI3K inhibitor alpelisib in head & neck squamous cell carcinoma
US20230374505A1 (en) Human XIST Antisense Oligonucleotides for X Reactivation Therapy
US20220387546A1 (en) Methods For Treating And/Or Preventing Hypersomnias
Mondal The super-enhancer driven lncRNA PRKCQ-AS1 promotes neuroblastoma tumorigenesis
AU2024311377A1 (en) Antisense oligonucleotides targeting mir-34a-5p and methods of use thereof
Scullion Investigation of the role of the epigenetic regulator UHRF1 in human cells
WO2025096404A1 (en) Compositions and methods for hemoglobin production
WO2021133874A1 (en) Compositions and methods for hemoglobin production
Aslibekyan et al. Epigenetics in Cardiovascular